

Beata Halassy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1134523/publications.pdf>

Version: 2024-02-01

62
papers

722
citations

516710

16
h-index

677142

22
g-index

63
all docs

63
docs citations

63
times ranked

799
citing authors

#	ARTICLE	IF	CITATIONS
1	Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?. <i>Frontiers in Immunology</i> , 2022, 13, 816159.	4.8	3
2	Development of Improved High-Performance Liquid Chromatography Method for the Determination of Residual Caprylic Acid in Formulations of Human Immunoglobulins. <i>Molecules</i> , 2022, 27, 1665.	3.8	2
3	ChAdOx1 adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination. <i>European Journal of Immunology</i> , 2022, 52, 936-945.	2.9	12
4	Efficient and Sustainable Platform for Preparation of a High-Quality Immunoglobulin G as an Urgent Treatment Option During Emerging Virus Outbreaks. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	2
5	Roughness of Production Conditions: Does It Really Affect Stability of IgG-Based Antivenoms?. <i>Toxins</i> , 2022, 14, 483.	3.4	3
6	Impact of complement and difference of cell-based assay and ELISA in determination of neutralization capacity against mumps and measles virus. <i>Journal of Immunological Methods</i> , 2021, 490, 112957.	1.4	5
7	Comparison of Preclinical Properties of Several Available Antivenoms in the Search for Effective Treatment of <i>Vipera ammodytes</i> and <i>Vipera berus</i> Envenoming. <i>Toxins</i> , 2021, 13, 211.	3.4	5
8	Intravenous <i>Vipera berus</i> Venom-Specific Fab Fragments and Intramuscular <i>Vipera ammodytes</i> Venom-Specific F(ab ²) Fragments in <i>Vipera ammodytes</i> -Envenomed Patients. <i>Toxins</i> , 2021, 13, 279.	3.4	3
9	Compassionate mesenchymal stem cell treatment in a severe COVID-19 patient: a case report. <i>Croatian Medical Journal</i> , 2021, 62, 288-296.	0.7	12
10	COVID-19 convalescent plasma therapy for immunodeficient patients—weighing up risks and benefits. <i>Transfusion Clinique Et Biologique</i> , 2021, 28, 424-425.	0.4	2
11	COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?. <i>Transfusion Clinique Et Biologique</i> , 2021, 28, 264-270.	0.4	23
12	Production- and Purification-Relevant Properties of Human and Murine Cytomegalovirus. <i>Viruses</i> , 2021, 13, 2481.	3.3	0
13	Quality-Related Properties of Equine Immunoglobulins Purified by Different Approaches. <i>Toxins</i> , 2020, 12, 798.	3.4	7
14	Biological Activities and Proteomic Profile of the Venom of <i>Vipera ursinii</i> ssp., a very Rare Karst Viper from Croatia. <i>Toxins</i> , 2020, 12, 187.	3.4	7
15	Streamlined downstream process for efficient and sustainable (Fab') ₂ antivenom preparation. <i>Journal of Venomous Animals and Toxins Including Tropical Diseases</i> , 2020, 26, e20200025.	1.4	4
16	Refinement strategy for antivenom preparation of high yield and quality. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007431.	3.0	17
17	Challenges in antivenom downstream processing efficiency estimation. <i>Toxicon</i> , 2019, 159, S6.	1.6	0
18	Concept of sample-specific correction of immunoassay results for precise and accurate IgG quantification in horse plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 164, 276-282.	2.8	6

#	ARTICLE	IF	CITATIONS
19	Comment on "Antivenom for European <i>Vipera</i> species envenoming". <i>Clinical Toxicology</i> , 2018, 56, 909-910.	1.9	0
20	Mass spectrometry-based investigation of measles and mumps virus proteome. <i>Virology Journal</i> , 2018, 15, 160.	3.4	10
21	Investigation of the thermal shift assay and its power to predict protein and virus stabilizing conditions. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 161, 73-82.	2.8	14
22	<i>Vipera ammodytes</i> bites treated with antivenom ViperaTAB: a case series with pharmacokinetic evaluation. <i>Clinical Toxicology</i> , 2017, 55, 241-248.	1.9	20
23	Recovery of infective virus particles in ion-exchange and hydrophobic interaction monolith chromatography is influenced by particle charge and total-to-infective particle ratio. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1054, 10-19.	2.3	29
24	A Single Dose of Vipervax™ May Be Inadequate for <i>Vipera ammodytes</i> Snake Bite: A Case Report and Pharmacokinetic Evaluation. <i>Toxins</i> , 2016, 8, 244.	3.4	11
25	Nonspecific native elution of proteins and mumps virus in immunoaffinity chromatography. <i>Journal of Chromatography A</i> , 2016, 1447, 107-114.	3.7	14
26	Venomics of <i>Vipera berus berus</i> to explain differences in pathology elicited by <i>Vipera ammodytes ammodytes</i> envenomation: Therapeutic implications. <i>Journal of Proteomics</i> , 2016, 146, 34-47.	2.4	47
27	Simple alternative to sialic acid determination in meningococcal polysaccharides W or Y. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 120, 283-289.	2.8	0
28	Identification of mumps virus protein and lipid composition by mass spectrometry. <i>Virology Journal</i> , 2016, 13, 9.	3.4	9
29	Optimization of tetanus toxoid ammonium sulfate precipitation process using response surface methodology. <i>Preparative Biochemistry and Biotechnology</i> , 2016, 46, 695-703.	1.9	5
30	Stability, biophysical properties and effect of ultracentrifugation and diafiltration on measles virus and mumps virus. <i>Archives of Virology</i> , 2016, 161, 1455-1467.	2.1	22
31	Stability of Minimum Essential Medium functionality despite L-glutamine decomposition. <i>Cytotechnology</i> , 2016, 68, 1171-1183.	1.6	11
32	Structural and biochemical characterisation of VaF1, a P-IIIa fibrinogenolytic metalloproteinase from <i>Vipera ammodytes ammodytes</i> venom. <i>Biochimie</i> , 2015, 109, 78-87.	2.6	9
33	Factors influencing preclinical <i>in vivo</i> evaluation of mumps vaccine strain immunogenicity. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2446-2454.	3.3	7
34	Identification of proteins interacting with ammodytoxins in <i>Vipera ammodytes ammodytes</i> venom by immuno-affinity chromatography. <i>Analytical and Bioanalytical Chemistry</i> , 2014, 406, 293-304.	3.7	17
35	VaSP1, catalytically active serine proteinase from <i>Vipera ammodytes ammodytes</i> venom with unconventional active site triad. <i>Toxicon</i> , 2014, 77, 93-104.	1.6	8
36	Hemorrhagin VaH4, a covalent heterodimeric P-III metalloproteinase from <i>Vipera ammodytes ammodytes</i> with a potential antitumour activity. <i>Toxicon</i> , 2014, 77, 141-155.	1.6	15

#	ARTICLE	IF	CITATIONS
37	Paraspecificity of Vipera a. ammodytes-specific antivenom towards Montivipera raddei and Macrovipera lebetina obtusa venoms. <i>Toxicon</i> , 2014, 78, 103-112.	1.6	15
38	VaH3, one of the principal hemorrhagins in Vipera ammodytes ammodytes venom, is a homodimeric P-IIIc metalloproteinase. <i>Biochimie</i> , 2013, 95, 1158-1170.	2.6	20
39	Influence of charge ratio of liposome/DNA complexes on their size after extrusion and transfection efficiency. <i>International Journal of Nanomedicine</i> , 2012, 7, 393.	6.7	23
40	The standard mouse assay of anti-venom quality does not measure antibodies neutralising the haemorrhagic activity of Vipera ammodytes venom. <i>Toxicon</i> , 2012, 59, 709-717.	1.6	12
41	Chromatography, mass spectrometry, and molecular modeling studies on ammodytoxins. <i>Analytical and Bioanalytical Chemistry</i> , 2012, 402, 2737-2748.	3.7	4
42	Ammodytagin, a heterodimeric metalloproteinase from Vipera ammodytes ammodytes venom with strong hemorrhagic activity. <i>Toxicon</i> , 2011, 58, 570-582.	1.6	18
43	Studying disulfide bond rearrangement by MALDI-TOF PSD and MALDI-TOF/RTOF high-energy CID (20 keV) experiments of peptides derived from ammodytoxins. <i>Journal of Mass Spectrometry</i> , 2011, 46, 153-162.	1.6	10
44	Intraspecies variability in Vipera ammodytes ammodytes venom related to its toxicity and immunogenic potential. <i>Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology</i> , 2011, 153, 223-230.	2.6	11
45	Concentration and purification of rubella virus using monolithic chromatographic support. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2011, 879, 981-986.	2.3	32
46	Ammodytoxin content of Vipera ammodytes ammodytes venom as a prognostic factor for venom immunogenicity. <i>Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology</i> , 2010, 151, 455-460.	2.6	4
47	Comparative study of structurally related peptidoglycan monomer and muramyl dipeptide on humoral IgG immune response to ovalbumin in mouse. <i>International Immunopharmacology</i> , 2010, 10, 751-759.	3.8	14
48	Robustness testing of live attenuated rubella vaccine potency assay using fractional factorial design of experiments. <i>Vaccine</i> , 2010, 28, 5497-5502.	3.8	9
49	Liposome fusogenicity and entrapment efficiency of antigen determine the Th1/Th2 bias of antigen-specific immune response. <i>Vaccine</i> , 2009, 27, 5435-5442.	3.8	33
50	The role of antibodies specific for toxic sPLA2s and hemorrhagins in neutralizing potential of antisera raised against Vipera ammodytes ammodytes venom. <i>Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology</i> , 2008, 148, 178-183.	2.6	10
51	Immunomodulatory activity of novel adjuvant formulations based on Montanide ISA oil-based adjuvants and peptidoglycan monomer. <i>International Immunopharmacology</i> , 2008, 8, 717-724.	3.8	19
52	Comparison of mouse and rabbit model for the assessment of strong PGM-containing oil-based adjuvants. <i>Veterinary Immunology and Immunopathology</i> , 2008, 121, 232-240.	1.2	5
53	Generation of ammodytoxin-anti-cathepsin B immuno-conjugate as a model for delivery of secretory phospholipase A2 into cancer cells. <i>Toxicon</i> , 2008, 51, 754-764.	1.6	4
54	Dose dependent effects of standardized nose-horned viper (Vipera ammodytes ammodytes) venom on parameters of cardiac function in isolated rat heart. <i>Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology</i> , 2008, 147, 434-440.	2.6	4

#	ARTICLE	IF	CITATIONS
55	Effectiveness of novel PGM-containing incomplete Seppic adjuvants in rabbits. <i>Vaccine</i> , 2007, 25, 3475-3481.	3.8	20
56	Use of Convective Interaction Media for Analysis of Longâ€Nosed Viper Venom. <i>Journal of Liquid Chromatography and Related Technologies</i> , 2007, 31, 38-53.	1.0	5
57	Determination of DNA entrapment into liposomes using short monolithic columns. <i>Journal of Chromatography A</i> , 2007, 1144, 150-154.	3.7	9
58	Purification and Characterization of L(L/D)â€Amino peptidase from Guinea Pig Serum. <i>Preparative Biochemistry and Biotechnology</i> , 2006, 36, 175-195.	1.9	3
59	Immunogenicity of peptides of measles virus origin and influence of adjuvants. <i>Vaccine</i> , 2006, 24, 185-194.	3.8	17
60	Effect of Liposomal Formulations and Immunostimulating Peptidoglycan Monomer (PGM) on the Immune Reaction to Ovalbumin in Mice. <i>Journal of Liposome Research</i> , 2006, 16, 1-16.	3.3	23
61	The variability of <i>Vipera ammodytes ammodytes</i> venoms from Croatiaâ€”biochemical properties and biological activity. <i>Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology</i> , 2005, 140, 257-263.	2.6	14
62	Adjuvant activity of peptidoglycan monomer and its metabolic products. <i>Vaccine</i> , 2003, 21, 971-976.	3.8	23